Thioredoxin-interacting protein seen as drug target

Pharmacological suppression of thioredoxin-interacting protein (TXNIP) may improve outcomes in many cardiovascular disease states and in diabetes, according to a paper published by Australian researchers.

It is likely that targeting TXNIP may rescue pancreatic beta-cells or cardiomyocytes from apoptosis in the presence of diabetes, much like ACE-inhibitors for early renal dysfunction, they say.

TXNIP is synthesized in response to increased blood sugar levels and abnormal wall stresses in blood vessels, and is implicated in many